ASCO 2019 | Highlights of the randomized phase III COLUMBA study

Maria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, talks to the MM Hub at ASCO 2019 about the phase III COLUMBA results. The study reports that subcutaneous administration of daratumumab (dara-SC) is non-inferior to intravenous administration (dara-IV). In a satisfaction questionnaire, patients reported a more favorable experience with dara-SC making it an attractive and viable option, both in terms of efficacy, and patient quality-of-life. Professor Mateos added that she believes daratumumab will be mainly administered subcutaneously, in the near future.

Maria-Victoria Mateos kindly gave her interview in Spanish, with the title: Resultados del ensayo randomizado fase III COLUMBA.